Decavèle Maxens, Parrot Antoine, Duruisseaux Michaël, Antoine Martine, Fajac Anne, Milon Audrey, Carette Marie-France, Canellas Anthony, Gibelin Aude, Elabbadi Alexandre, Wislez Marie, Cadranel Jacques, Fartoukh Muriel
Groupe Hospitalier Universitaire APHP-Sorbonne Université, Hôpital Tenon, Service de Médecine Intensive Réanimation, Paris, France.
Sorbonne Université, INSERM, UMRS1158 Neurophysiologie Respiratoire Expérimentale et Clinique, Paris, France.
J Thorac Dis. 2022 Aug;14(8):2812-2825. doi: 10.21037/jtd-22-12.
The absence of diagnosis of acute respiratory distress syndrome (ARDS) concerns 20% of cancer patients and is associated with poorer outcomes. Diffuse pneumonic-type adenocarcinoma (P-ADC) is part of these difficult-to-diagnose ARDS, but only limited data are available regarding critically ill patients with diffuse P-ADC. We sought to describe the diagnosis process and the prognosis of P-ADC related ARDS patients admitted to the intensive care unit (ICU).
Single-center observational case series study. All consecutive patients admitted to the ICU over a two-decade period presenting with (I) histologically or cytologically proven adenocarcinoma of the lung and (II) ARDS according to Berlin definition were included. Clinical, biological, radiological and cytological features of P-ADC were collected to identify diagnostic clues. Multivariate logistic regression analyses were performed to assess factors associated with ICU and hospital mortality.
Among the 24 patients included [70 (61-75) years old, 17 (71%) males], the cancer diagnosis was performed during the ICU stay in 19 (79%), and 17 (71%) required mechanical ventilation. The time between the first symptoms and the diagnosis of P-ADC was 210 days (92-246 days). A non-resolving pneumonia after 2 (2 to 3) antibiotics lines observed in 23 (96%) patients with a 34 mg/L (19 to 75 mg/L) plasma C-reactive protein level at ICU admission. Progressive dyspnea, bronchorrhea, salty expectoration, fissural bulging and compressed bronchi and vessels were present in 100%, 83%, 69%, 57% and 43% of cases. Cytological examination of sputum or broncho-alveolar lavage provided a 75% diagnostic yield. The ICU and hospital mortality rates were 25% and 63%, respectively. The time (in days) between first symptoms and diagnosis [odds ratio (OR) 1.02, 95% confidence interval (95% CI): 1.00-1.03, P=0.046] and the Simplified Acute Physiology Score II (OR 1.16, 95% CI: 1.01-1.33, P=0.040) were independently associated with ICU mortality.
Non-resolving pneumonia after several antibiotics lines without inflammatory syndrome, associated with progressive dyspnea, salty bronchorrhea, and lobar swelling (i.e., fissural bulging, compressed bronchi and vessels) were suggestive of P-ADC. Delayed diagnosis of diffuse P-ADC seemed an independent prognostic predictor and disease timely recognition may contribute to prognosis improvement.
20%的癌症患者未被诊断出急性呼吸窘迫综合征(ARDS),且这与较差的预后相关。弥漫性肺炎型腺癌(P-ADC)是这些难以诊断的ARDS的一部分,但关于患有弥漫性P-ADC的重症患者的数据有限。我们试图描述入住重症监护病房(ICU)的P-ADC相关ARDS患者的诊断过程和预后。
单中心观察性病例系列研究。纳入在二十年期间连续入住ICU且符合以下条件的所有患者:(I)经组织学或细胞学证实的肺腺癌,以及(II)根据柏林定义诊断为ARDS。收集P-ADC的临床、生物学、放射学和细胞学特征以识别诊断线索。进行多变量逻辑回归分析以评估与ICU和医院死亡率相关的因素。
纳入的24例患者[年龄70(61 - 75)岁,男性17例(71%)]中,19例(79%)在ICU住院期间确诊癌症,17例(71%)需要机械通气。从首次出现症状到诊断P-ADC的时间为210天(92 - 246天)。23例(96%)患者在使用2(2至3)种抗生素治疗后肺炎仍未缓解,入住ICU时血浆C反应蛋白水平为34 mg/L(19至75 mg/L)。100%、83%、69%、57%和43%的病例分别出现进行性呼吸困难、支气管溢液、咸味痰液、叶间裂膨出以及支气管和血管受压。痰液或支气管肺泡灌洗的细胞学检查诊断阳性率为75%。ICU死亡率和医院死亡率分别为25%和63%。首次症状与诊断之间的时间(天数)[比值比(OR)1.02,95%置信区间(95%CI):1.00 - 1.03,P = 0.046]和简化急性生理学评分II(OR 1.16,95%CI:1.01 - 1.33,P = 0.040)与ICU死亡率独立相关。
在使用多种抗生素治疗后肺炎仍未缓解且无炎症综合征,同时伴有进行性呼吸困难、咸味支气管溢液和肺叶肿胀(即叶间裂膨出、支气管和血管受压)提示为P-ADC。弥漫性P-ADC的延迟诊断似乎是一个独立的预后预测因素,及时识别疾病可能有助于改善预后。